Dr. Cohen will also be an Associate Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai. In these roles, she will conduct important translational and clinical research, including studies that build upon scientific discoveries developed at Mount Sinai and collaborating institutions.
As Director of the GI Oncology Program, Dr. Cohen will foster both clinical and research activities associated with GI cancers across the Mount Sinai cancer sites. She will also oversee the development of clinical trials in her role as Medical Director of the Cancer Clinical Trials Office. Dr. Cohen has abundant experience as Principal Investigator on numerous trials for novel therapeutic approaches for gastrointestinal cancer in particular.
“We are very proud that Dr. Cohen has decided to join us to help lead our efforts in gastrointestinal cancers,” said Ramon Parsons, MD, PhD, Director of The Tisch Cancer Institute at Mount Sinai, Chair of Oncological Sciences, and Ward-Coleman Professor in Cancer Research of the Icahn School of Medicine at Mount Sinai. “We are excited to welcome her to also further develop our already robust clinical trial office.”
Prior to joining Mount Sinai, Dr. Cohen was on the faculty in the Division of Medical Oncology at New York University (NYU) for 13 years. Recently, she served as Medical Director for the Perlmutter Cancer Center Clinical Trials Office and Acting Director of NYU GI Medical Oncology. Board certified in internal medicine, medical oncology, and hematology, Dr. Cohen is a member of the American Society of Clinical Oncology and the National Cancer Institute Colon Task Force.
Dr. Cohen received her MD from SUNY Health Science Center at Brooklyn and a Master of Science in Clinical Investigation from New York University. She completed a residency in internal medicine at NewYork-Presbyterian/Weill Cornell Medical Center and a fellowship in hematology/oncology at NYU Langone School of Medicine.
“Dr. Cohen’s arrival is an exciting step forward for coordinating a multidisciplinary approach for gastrointestinal cancer that builds on a strong foundation already here,” said William K. Oh, MD, Chief of Hematology and Medical Oncology and Deputy Director of The Tisch Cancer Institute at Mount Sinai and the Ezra M. Greenspan, M.D. Professor in Clinical Cancer Care Therapeutics. “We are driven to continue to develop more effective therapies in trials for a constellation of cancers that take so many lives every year.”
About the Mount Sinai Health System
The Mount Sinai Health System is New York City’s largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report’s “Honor Roll” of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians in the top 1% of all physicians nationally by U.S. News & World Report.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.